Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 1085

1.

The characterization, management, and future considerations for ErbB-family TKI-associated diarrhea.

Rugo HS, Di Palma JA, Tripathy D, Bryce R, Moran S, Olek E, Bosserman L.

Breast Cancer Res Treat. 2019 Jan 22. doi: 10.1007/s10549-018-05102-x. [Epub ahead of print] Review.

PMID:
30671765
2.

Intestinal epithelial potassium channels and CFTR chloride channels activated in ErbB tyrosine kinase inhibitor diarrhea.

Duan T, Cil O, Thiagarajah JR, Verkman AS.

JCI Insight. 2019 Jan 22. pii: 126444. doi: 10.1172/jci.insight.126444. [Epub ahead of print]

PMID:
30668547
3.

Overcoming Intrinsic and Acquired Cetuximab Resistance in RAS Wild-Type Colorectal Cancer: An In Vitro Study on the Expression of HER Receptors and the Potential of Afatinib.

De Pauw I, Lardon F, Van den Bossche J, Baysal H, Pauwels P, Peeters M, Vermorken JB, Wouters A.

Cancers (Basel). 2019 Jan 15;11(1). pii: E98. doi: 10.3390/cancers11010098.

4.

Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China.

Gu X, Zhang Q, Chu YB, Zhao YY, Zhang YJ, Kuo D, Su B, Wu B.

Lung Cancer. 2019 Jan;127:84-89. doi: 10.1016/j.lungcan.2018.11.029. Epub 2018 Nov 24.

PMID:
30642557
5.

Efficacy of afatinib or osimertinib plus cetuximab combination therapy for non-small-cell lung cancer with EGFR exon 20 insertion mutations.

Hasegawa H, Yasuda H, Hamamoto J, Masuzawa K, Tani T, Nukaga S, Hirano T, Kobayashi K, Manabe T, Terai H, Ikemura S, Kawada I, Naoki K, Soejima K.

Lung Cancer. 2019 Jan;127:146-152. doi: 10.1016/j.lungcan.2018.11.039. Epub 2018 Nov 29.

PMID:
30642543
6.

Impact of afatinib dose modification on safety and effectiveness in patients with EGFR mutation-positive advanced NSCLC: Results from a global real-world study (RealGiDo).

Halmos B, Tan EH, Soo RA, Cadranel J, Lee MK, Foucher P, Hsia TC, Hochmair M, Griesinger F, Hida T, Kim E, Melosky B, Märten A, Carcereny E.

Lung Cancer. 2019 Jan;127:103-111. doi: 10.1016/j.lungcan.2018.10.028. Epub 2018 Nov 2.

7.

Isolation and structural characterization of degradation products of afatinib dimaleate by LC-Q-TOF/MS/MS and NMR: cytotoxicity evaluation of afatinib and isolated degradation products.

Chavan BB, Sawant V, Borkar RM, Ragampeta S, Talluri MVNK.

J Pharm Biomed Anal. 2019 Jan 7;166:139-146. doi: 10.1016/j.jpba.2019.01.004. [Epub ahead of print]

PMID:
30640044
8.

Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, phase I trial with an extensive biomarker program.

Moehler M, Maderer A, Ehrlich A, Foerster F, Schad A, Nickolay T, Ruckes C, Weinmann A, Sivanathan V, Marquardt JU, Galle PR, Woerns M, Thomaidis T.

BMC Cancer. 2019 Jan 11;19(1):55. doi: 10.1186/s12885-018-5223-7.

9.

PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers.

Bonazzoli E, Cocco E, Lopez S, Bellone S, Zammataro L, Bianchi A, Manzano A, Yadav G, Manara P, Perrone E, Haines K, Espinal M, Dugan K, Menderes G, Altwerger G, Han C, Zeybek B, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin AD.

Gynecol Oncol. 2019 Jan 7. pii: S0090-8258(19)30004-6. doi: 10.1016/j.ygyno.2019.01.002. [Epub ahead of print]

PMID:
30630630
10.
11.

Personalized Prediction of Acquired Resistance to EGFR-Targeted Inhibitors Using a Pathway-Based Machine Learning Approach.

Kim YR, Kim YW, Lee SE, Yang HW, Kim SY.

Cancers (Basel). 2019 Jan 4;11(1). pii: E45. doi: 10.3390/cancers11010045.

12.

Brief Report: EGFR and ERBB2 Germline Mutations in Chinese Lung Cancer Patients and Their Roles in Genetic Susceptibility to Cancer.

Lu S, Yu Y, Li Z, Yu R, Wu X, Bao H, Ding Y, Shao YW, Jian H.

J Thorac Oncol. 2019 Jan 2. pii: S1556-0864(18)33515-9. doi: 10.1016/j.jtho.2018.12.006. [Epub ahead of print]

PMID:
30610926
13.

First- and Second-Generation EGFR-TKIs Are All Replaced to Osimertinib in Chemo-Naive EGFR Mutation-Positive Non-Small Cell Lung Cancer?

Takeda M, Nakagawa K.

Int J Mol Sci. 2019 Jan 3;20(1). pii: E146. doi: 10.3390/ijms20010146. Review.

14.

Successful treatment of a lung adenocarcinoma patient with a novel EGFR exon 20-ins mutation with afatinib: A case report.

Cai Y, Wang X, Guo Y, Sun C, Xu Y, Qiu S, Ma K.

Medicine (Baltimore). 2019 Jan;98(1):e13890. doi: 10.1097/MD.0000000000013890.

15.

Successful Treatment of Lung Adenocarcinoma with Epidermal Growth Factor Receptor Compound Mutations Involving Exon 19 Deletion and Exon 20 Insertion by Afatinib.

Ikeuchi T, Tokuyasu H, Ishikawa S.

Intern Med. 2019;58(1):101-104. doi: 10.2169/internalmedicine.0927-18. Epub 2019 Jan 1.

16.

Discovery of new quinazoline derivatives as irreversible dual EGFR/HER2 inhibitors and their anticancer activities - Part 1.

Das D, Xie L, Wang J, Xu X, Zhang Z, Shi J, Le X, Hong J.

Bioorg Med Chem Lett. 2018 Dec 24. pii: S0960-894X(18)31002-3. doi: 10.1016/j.bmcl.2018.12.056. [Epub ahead of print]

PMID:
30600209
17.

HER2 exon 20 insertions in Non-Small Cell Lung Cancer are Sensitive to the Irreversible Pan-HER Receptor Tyrosine Kinase Inhibitor Pyrotinib.

Wang Y, Jiang T, Qin Z, Jiang J, Wang Q, Yang S, Rivard C, Gao G, Ng TL, Tu MM, Yu H, Ji H, Zhou C, Ren S, Zhang J, Bunn P, Doebele RC, Camidge DR, Hirsch FR.

Ann Oncol. 2018 Dec 31. doi: 10.1093/annonc/mdy542. [Epub ahead of print]

PMID:
30596880
18.

Drug-Drug Interactions, Safety, and Pharmacokinetics of EGFR Tyrosine Kinase Inhibitors for the Treatment of Non-Small Cell Lung Cancer.

Kucharczuk CR, Ganetsky A, Vozniak JM.

J Adv Pract Oncol. 2018 Mar;9(2):189-200. Epub 2018 Mar 1. Review.

19.

Clinical benefit from afatinib in an advanced squamous cell lung carcinoma patient harboring HER2 S310Y mutation: a case report.

Gao Y, Zheng A, Zhu X, Song J, Xue Q.

Onco Targets Ther. 2018 Dec 5;11:8705-8710. doi: 10.2147/OTT.S182812. eCollection 2018.

20.

Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations: subgroup analysis of the LUX-Lung 6 trial.

Wu YL, Xu CR, Hu CP, Feng J, Lu S, Huang Y, Li W, Hou M, Shi JH, Märten A, Fan J, Peil B, Zhou C.

Onco Targets Ther. 2018 Nov 30;11:8575-8587. doi: 10.2147/OTT.S160358. eCollection 2018.

Supplemental Content

Loading ...
Support Center